# US 2023/0069065 A1 · Novel corneal tissues and methods of making the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0069065 A1
- Document ID: US20230069065A1
- Status: Published application
- Kind: A1
- Application number: 17/759,786
- Filed: 2021-01-29
- Published: 2023-03-02
- Earliest claimed: 2020-01-30
- Applicants: 3D Bio-tissues Limited
- Inventors: Che John CONNON; Ricardo GOUVEIA
- Web page: https://patentgrep.com/patent/US20230069065A1

## CPC

- A61F 2/142: {Cornea, e.g. artificial corneae, keratoprostheses or corneal implants for repair of defective corneal tissue}
- A61K 35/30: Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C12N 5/0621: {Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N5/062)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2533/54: Collagen; Gelatin
- C12N 2535/00: Supports or coatings for cell culture characterised by topography
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to novel methods for making transparent and curved stromal cell tissues and decellularized forms thereof. Novel tissues are also provided.

## Claims

### Claim 1

A method of making a transparent and curved stromal cell tissue having a minimum thickness of at least 50 μm, the method comprising:
i) encapsulating or entrapping stromal cells in a hydrogel, wherein the hydrogel comprises cell adhesion motifs;
ii) transferring the hydrogel onto a curved surface; and
iii) retaining the hydrogel on the curved surface under appropriate cell culture conditions for at least twenty four hours to generate a curved stromal cell tissue with a minimum visible light transmittance value of at least 0.5, wherein the curved surface has a curvature of from about 0.04 to about 0.5 mm−1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cell adhesion motif is an extracellular matrix protein sequence or a fragment or a variant thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the extracellular matrix protein is selected from the group consisting of fibronectin, collagen, lumican, decorin, laminin, vitronectin, fibrinogen, elastin, biglycan, heparin, tenascin and osteopontin.

### Claim 4 (depends on 3)

The method of claim 3, wherein the cell adhesion motif is:
a) a fibronectin fragment comprising or consisting of an amino acid sequence selected from RGD (SEQ ID NO: 1), RGDS (SEQ ID NO: 5), PHSRN (SEQ ID NO: 6), LDVP (SEQ ID NO: 7), WQPPRARI (SEQ ID NO: 8), IGD (SEQ ID NO: 9), REDV (SEQ ID NO: 10), and IDAP (SEQ ID NO: 11) or a variant thereof;
b) a collagen fragment comprising or consisting of an amino acid sequence selected from KTTKS (SEQ ID NO:2), GTPGPQGIAGQRGVV (SEQ ID NO: 12), GROGER (SEQ ID NO: 13, GLKGEN (SEQ ID NO: 14), GFOGER (SEQ ID NO: 15), and MNYYSNS (SEQ ID NO: 16) or a variant thereof; or
c) a lumican fragment comprising or consisting of an amino acid sequence selected from EVTLN (SEQ ID NO: 17), ELDLSYNKLK (SEQ ID NO: 18) and YEALRVANEVTLN (SEQ ID NO: 3); or
d) a laminin fragment comprising or consisting of an amino acid sequence selected from the YIGSR (SEQ ID NO: 19), IKVAV (SEQ ID NO: 20), CCRRIKVAVWLC (SEQ ID NO: 21) and RGD.

### Claim 5

The method of any preceding claim, wherein the hydrogel has a total gel density of from about 0.25 to about 0.50 g/cm3.

### Claim 6

The method of any preceding claim, wherein the hydrogel has a gel hydration of from about 70% to about 90%.

### Claim 7

The method of any preceding claim, wherein the hydrogel has a gel stiffness of from about 0.5 to about 35×106 Pa.

### Claim 8

The method of any preceding claim, wherein the hydrogel has a thickness of from about 0.1 to 12.0 mm.

### Claim 9

The method of any preceding claim, wherein the hydrogel has a collagen density of from about 0.07 to about 0.3 g/cm3.

### Claim 10

The method of any preceding claim, wherein the hydrogel is in the form of a thin layer or disc.

### Claim 11

The method of any preceding claim, wherein the cell culture conditions comprise retaining the hydrogel on the curved surface in cell culture medium.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cell culture medium is Dulbecco's Modified Eagle Medium (DMEM), Ham's F12 or DMEM-F12.

### Claim 13 (depends on 11, 12)

The method of claim 11 or 12, wherein the cell culture medium is serum free.

### Claim 14 (depends on 11, 12, 13)

The method of any of claims 11 to 13, wherein the cell culture medium comprises retinoic acid.

### Claim 15 (depends on 11, 12, 13, 14)

The method of any of claims 11 to 14, wherein the cell culture medium comprises KTTKS lipopeptides in solution.

### Claim 16

The method of any preceding claim, wherein the curved surface is a polystyrene, polyethylene, polyethylene terephthalate, polylactic acid, polycarbonate, acrylonitrile butadiene styrene, agarose, a hydrogel or a glass surface, optionally wherein the glass surface is a borosilicate glass surface.

### Claim 17

The method of any preceding claim, wherein the hydrogel is maintained on the curved surface under appropriate cell culture conditions for at least four days.

### Claim 18

The method of any preceding claim, wherein the stromal cells are corneal stromal cells.

### Claim 19 (depends on 18)

The method of claim 18, wherein the corneal stromal cells are corneal fibroblasts.

### Claim 20

The method of any preceding claim, wherein the stromal cells are human.

### Claim 21 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any of claims 2 to 20, wherein the stromal cells are from a first species and the extracellular matrix protein sequence is from a second species.

### Claim 22

The method of any preceding claim, wherein the hydrogel comprising cell adhesion motifs is generated by extruding the hydrogel onto the curved surface, optionally wherein the hydrogel is generated using 3D bio-printing.

### Claim 23

The method of any preceding claim, wherein the stromal cell tissue is subsequently decellularized.

### Claim 24 (depends on 21, 22)

A stromal cell tissue obtainable or obtained by a method according to claim 21 or 22.

### Claim 25 (depends on 23)

A decellularized tissue obtainable or obtained by a method according to claim 23.

### Claim 26

A stromal cell tissue having a minimum thickness of at least 50 μm, a minimum visible light transmittance value of at least 0.5 and a curvature of from about 0.04 to about 0.5 mm−1, wherein the tissue comprises:
a) stromal cells from a first species and
b) trace amounts of:
(i) an extracellular matrix protein sequence from a second species, or a fragment or a variant thereof; or
(ii) a synthetic extracellular matrix protein sequence or a fragment or a variant thereof.

### Claim 27 (depends on 26)

The stromal cell tissue of claim 26, wherein the first species is human and the second species is non-human.

### Claim 28 (depends on 26, 27)

The stromal cell tissue of claim 26 or 27, wherein the stromal cells are corneal stromal cells.

### Claim 29 (depends on 28)

The stromal cell tissue of claim 28, wherein the corneal stromal cells are corneal fibroblasts.

### Claim 30

A decellularized tissue having a minimum thickness of at least 50 μm, a minimum visible light transmittance value of at least 0.5 and a curvature of from about 0.04 and about 0.5 mm−1, wherein the tissue comprises:
a) extracellular matrix protein sequences from a first species and
b) trace amounts of:
(i) an extracellular matrix protein sequence from a second species, or a fragment or a variant thereof; or
(ii) a synthetic extracellular matrix protein sequence or a fragment or a variant thereof.

### Claim 31 (depends on 30)

The decellularized tissue of claim 30, wherein the first species is human, and the second species is non-human.

### Claim 32 (depends on 26, 27, 28, 29, 30, 31)

The tissue of any of claims 26 to 31, wherein the tissue has a thickness of from about 0.1 to 12.0 mm.

### Claim 33 (depends on 26, 27, 28, 29, 30, 31, 32)

The tissue of any of claims 26 to 32, wherein the extracellular matrix protein sequence from a second species or synthetic extracellular matrix protein is collagen.

### Claim 34 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A tissue according to any of claims 24 to 33 for use in therapy.

### Claim 35 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

A tissue according to any of claims 24 to 33 for use in keratoplasty.
